Investors
Company Profile
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
Financial Reports
Sorry, there are no financial reports available yet.
Investor presentations
Results: PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor
Investor Presentation Conference Call 6th July, 2020
Investor Presentation Jefferies Virtual Healthcare Conference June 3rd, 2020
JP Morgan Healthcare Conference, San Francisco, 15th January 2020
Linzagolix Phase 3 PRIMROSE 2 Trial Results
Investor Presentation 10th Annual Jefferies Global Healthcare Conference 21 November 2019
Cantor Global Healthcare Conference October 4 2019
The H.C. Wainwright 21st Annual Global Investment in NYC – September 10th 2019
Press Releases
ObsEva SA to Hold Second Quarter 2017 Financial Results/Business Update Call on August 15, 2017 and Present at Wedbush PacGrow Healthcare Conference in NYC on August 16, 2017
press release
August 7, 2017
Geneva, Switzerland and Boston, MA – 07 August, 2017 – ObsEva SA (NASDAQ: OBSV), a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics…
Read moreObsEva Announces Presentations Related to its Assisted Reproductive Technology (ART) and Pre-term labor (PTL) Development Programs at ESHRE 2017 Annual Meeting
press release
June 29, 2017
Phase 2 nolasiban previously reported data supports potential for meaningfully increasing live birth rates in ART Non-clinical results of OBE022…
Read moreObsEva SA Announces the Completion of a Phase 1 PK/PD Clinical Trial Evaluating Different Doses of OBE2109 and Add-Back Therapy
press release
June 7, 2017
– OBE2109 is a GnRH receptor antagonist currently in development as both a stand-alone treatment and with add-back therapy designed…
Read moreGeneral Meetings
ObsEva Annual General Meeting 2023
June 29, 2023
ObsEva Annual General Meeting 2022
May 18, 2022
Upcoming Events
Stock Information
Latest Press Release
ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listing
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 3, 2024 –…
Read moreInvestor Contact
Media Contact
Media
Contacts
ObsEva Switzerland Office
Chemin des Aulx,12
1228, Plan-Les-Ouates, Geneva, Switzerland
+41 (0)22 552 3840
Media
Sign up for news
